Dedicated to Innovation: Thromboresistance in Vascular Devices

    Gore’s CBAS® Heparin Surface, the proven heparin bonding technology for lasting thromboresistance, is used in many of our interventional and vascular surgery products. End-point covalent bonding keeps heparin anchored to the device, while the bioactive site remains free to interact with the blood to help prevent clotting.*

    • Proven heparin availability: Performance-ready heparin active site*,1,4
    • Proven heparin bioactivity: Unmatched, persistent ability to take up antithrombin*,2,3
    • Proven lasting thromboresistance: Improved surface hemocompatibility resulting from heparin availability and bioactivity*,1-5

      Proprietary covalent end-point bonding

      Covalent end-point bonding allows the heparin to extend into the bloodstream, keeping the active site bioavailable, unlike a non-permanent bond that can be washed away in the bloodstream.

      • The anticoagulant function of heparin is dependent on the bioavailability of an active site within the molecule. 
      • Some methods of covalent heparin bonding damage and / or obstruct the active site, and hence destroy heparin’s anticoagulant activity. 
      • The CBAS® Heparin Surface consists of a proprietary covalent end-point bond that preserves the active site, thus retaining heparin’s anticoagulant activity. 
      Proprietary covalent end-point bonding
      Mechanism of action

      Mechanism of action

      A. Bioactive site of the heparin molecule enables antithrombin to bind thrombin.
      B. When antithrombin binds to thrombin, a neutral thrombin antithrombin (TAT) complex is formed.
      C. Neutral TAT complex detaches from the heparin molecule. Active site becomes available to again bind antithrombin.

      *See full CBAS® Heparin Surface references

      Featured Gore Products with CBAS® Heparin Surface

       

      GORE® ACUSEAL Vascular Graft

      GORE® PROPATEN® Vascular Graft

      GORE® PROPATEN® Vascular Graft configured for Pediatric Shunt

      GORE® VIABAHN® Endoprosthesis with Heparin Bioactive Surface

      GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis

      1. Gore S, Andersson J, Biran R, Underwood C, Riesenfeld J. Heparin surfaces: impact of immobilization chemistry on hemocompatibility and protein adsorption. Journal of Biomedical Materials Research Part B: Applied Biomaterials 2014;102(8):1817-1824.
      2. Begovac PC, Thomson RC, Fisher JL, Hughson A, Gällhagen A. Improvements in GORE-TEX® Vascular Graft performance by Carmeda® BioActive Surface heparin immobilization. European Journal of Vascular & Endovascular Surgery 2003;25(5):432-437.
      3. Freeman J, Chen A, Weinberg RJ, Okada T, Chen C, Lin PH. Sustained thromboresistant bioactivity with reduced intimal hyperplasia of heparin-bonded PTFE Propaten Graft in a chronic canine femoral artery bypass model. Annals of Vascular Surgery 2018;49:295-303. 
      4. Biran R, Pond D. Heparin coatings for improving blood compatibility of medical devices. Advanced Drug Delivery Reviews 2017;112:12-23. 
      5. Carmeda AB. Carmeda® BioActive Surface (also known as CBAS® Heparin Surface) Reference List. Upplands Väsby, Sweden: Carmeda AB; 2019. [Reference list]

       

      22589259-EN